Focusing on Multiple Myeloma
The AACR is partnering with Takeda to support research to broaden our understanding of multiple myeloma and develop better treatments.
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell important for a healthy immune system. Over time, myeloma cells collect in the bone marrow, forming tumors in many of the body’s bones. These tumors may keep the bone marrow from making enough healthy blood cells and weaken the bone.
While the causes of
multiple myeloma are not fully understood, it is more common in older people, especially men, and African-Americans. Some common symptoms include bone pain, weakness or fatigue, weight loss, frequent infections, and frequent urination.
The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program
estimates that more than 30,700 people living in the United States were diagnosed with multiple myeloma in 2018 and that more than 12,700 died of the disease.
March is Multiple Myeloma Awareness Month.
What is the AACR Doing in This Area?
In October 2020, AACR will present a special conference on the topic of multiple myeloma, gathering the top researchers in the field.
In 2018, the AACR offered several awards to researchers whose research focuses on topics related to multiple myeloma:
- AACR Scholar-in-Training Award: Kevin C. Miller, Mayo Clinic; Tarek H. Mouhieddine, MD, Dana-Farber Cancer Institute
- AACR Minority and Minority-Serving Institution Faculty Scholars in Cancer Research: Edward A. Medina, MD, UT Health Science Center at San Antonio
Last year the AACR provided over $64 million in grants and awards funding lifesaving cancer research. There are many ways you can support our mission to prevent and cure all cancers.